Although patients could benefit from treatment with HMG-CoA reductase inhibitors, it has been shown that the concomitant use of cyclosporine with HMG-CoA reductase inhibitors increases the risk of myopathy and rhabdomyolysis due to a potential drug–drug interaction caused by the inhibition of the CYP3A-mediated metabolism of simvastatin and the inhibition by cyclosporine of the hepatic absorption of simvastatin mediated by organic ion transporter proteins (OATP1B1) [65]. The gene discussed is HMGCR; the disease is rhabdomyolysis.